Evaluation of Elexacaftor/Tezacaftor/Ivacaftor-Mediated Drug-Induced Liver Injury Using a Liver-On-Chip Model. [PDF]
Shi A, Agarwal P, Liu ZX, Beringer PM.
europepmc +1 more source
Advances in the restoration of CFTR in children and pwCF with "mild disease". [PDF]
Cohen-Cymberknoh M.
europepmc +1 more source
Understanding beliefs about elexacaftor-tezacaftor-ivacaftor therapy in adults living with cystic fibrosis. [PDF]
O'Leary C +5 more
europepmc +1 more source
Non-tuberculous mycobacterial infection in cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor: now is not the time to lower the guard. [PDF]
Evans IES +8 more
europepmc +1 more source
Respiratory Oscillometry and Multimodal Lung Function Assessment of Elexacaftor/Tezacaftor/Ivacaftor Response in Children and Young Adults With Cystic Fibrosis. [PDF]
Kogias C +8 more
europepmc +1 more source
Expanding the Impact of New Cystic Fibrosis Therapies in Low- and Middle-Income Countries. [PDF]
Kerem E.
europepmc +1 more source
The validated French CFAbd-Score reveals a lower burden of gastrointestinal symptoms in patients on Elexacaftor/Tezacaftor/Ivacaftor. [PDF]
Sermet-Gaudelus I +13 more
europepmc +1 more source
Comparison of Stool Microbiome in Children with Cystic Fibrosis Treated with and Without Elexacaftor-Tezacaftor-Ivacaftor-A Pilot Study. [PDF]
Sankararaman S +9 more
europepmc +1 more source
Modelling the Repair of Carbon-Centered Protein Radicals by Phenolic Antioxidants. [PDF]
Walton-Raaby M, Floen T, Mora-Diez N.
europepmc +1 more source

